Evidence map›Paper›PMID 26524589›Full record

ArticleThe Journal of clinical investigation2015

HA-ving lymphatics improves lung transplantation.

Jonathan S Maltzman, Hasina Outtz Reed, Mark L Kahn

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [Research on tissue regeneration and engineered scaffold materials in prevention and treatment of lymphedema].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jonathan S Maltzman
Hasina Outtz Reed
Mark L Kahn

Funding

TRAINING IN PULMONARY IMMUNOLOGYT32HL007586 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MEYER, NUALA JENNINGS · 1985 to 2025
$8.8M
Genetic Investigation of pulmonary lymphatic development and functionR01HL120872 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2014 to 2018
$2.0M
Signals Affecting Homestasis and Tolerance in Memory T CellsR01AI085160 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI MALTZMAN, JONATHAN S · 2010 to 2014
$1.9M
Role of CCBE1 in lymphatic vascular development and growthR01HL111553 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2013 to 2016
$1.6M
Foxp transcription factors in regulatory T cell development and homeostasisR56AI108786 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI MALTZMAN, JONATHAN S · 2014 to 2014
$396k
NHLBI NIH HHS HL111553NHLBI NIH HHS HL120872NHLBI NIH HHS R01 HL111553NHLBI NIH HHS R01 HL120872NHLBI NIH HHS T32 HL007586NIAID NIH HHS R01 AI085160NIAID NIH HHS R01-AI085160NIAID NIH HHS R56 AI108786NIAID NIH HHS R56-AI108786
6 · The paper itself

Abstract

Lung allografts are prone to rejection, even though recipients undergo aggressive immunosuppressive therapy. Lymphatic vessels serve as conduits for immune cell trafficking and have been implicated in the mediation of allograft rejection. In this issue of the JCI, Cui et al. provide compelling evidence that lymphatic vessel formation improves lung allograft survival in a murine transplant model. Moreover, their data suggest a potential mechanism for the beneficial effects of lymphatics that does not involve immune cell or antigen transport. Together, the results of this study provide new insight into the role of lymphatic vessels in transplant tolerance.

Indexed as

Lung TransplantationLymphangiogenesisAnimalsGraft RejectionHumansHyaluronic AcidMaleVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3Hyaluronic AcidVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3

Identifiers

PMID26524589
PMCPMC4639989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.